Casgevy

  Source: IE  Context: The UK drug regulator recently approved Casgevy, a gene therapy for sickle cell disease and thalassaemia, marking a breakthrough as the world’s first licensed therapy using Crispr-Cas9 gene editing technology.   What is Casgevy? It is a groundbreaking gene-editing therapy for sickle cell anaemia, utilizing the CRISPR-Cas9 tool. Casgevy edits the …